Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Non-cash Items (2019 - 2026)

Atea Pharmaceuticals' Non-cash Items history spans 8 years, with the latest figure at $26.6 million for Q1 2026.

  • Quarterly Non-cash Items rose 444.85% to $26.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.6 million through Mar 2026, up 444.85% year-over-year, with the annual reading at $8.4 million for FY2025, 38.41% up from the prior year.
  • Non-cash Items came in at $26.6 million for Q1 2026, up from $8.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $26.6 million in Q1 2026 to a low of $6070.0 in Q1 2023.
  • The 5-year median for Non-cash Items is $6.0 million (2024), against an average of $7.2 million.
  • Year-over-year, Non-cash Items plummeted 64.99% in 2022 and then soared 140954.37% in 2024.
  • Atea Pharmaceuticals' Non-cash Items stood at $10.9 million in 2022, then tumbled by 53.55% to $5.1 million in 2023, then increased by 19.98% to $6.1 million in 2024, then soared by 38.41% to $8.4 million in 2025, then soared by 215.24% to $26.6 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Non-cash Items are $26.6 million (Q1 2026), $8.4 million (Q4 2025), and $4.6 million (Q3 2025).